Davita Inc vs EHang Holdings Ltd - ADR — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while EHang Holdings Ltd - ADR trades at $4.12 (market cap $309.45M). The key difference: Davita Inc is far larger — about 36.5× EHang Holdings Ltd - ADR's market cap, and Davita Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and EHang Holdings Ltd - ADR for 46 Days on average.
| DVA | EH | |
|---|---|---|
Market Cap | $11.29B | $309.45M |
Volume | 582,204 | 765,799 |
Sector | Health | Industrials |
52-Week High | $240.96 | $18.94 |
52-Week Low | $103.87 | $4.03 |
Typical Hold Time | 113 Days | 46 Days |
Enterprise Value | $24.01B | $261.14M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and ROE. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a volatile backdrop.
The outlook remains challenging due to persistent losses and regulatory scrutiny, though the company's cash position of $1.12 billion provides some buffer. Investment opportunities hinge on successful commercialization of eVTOL technology, while risks include execution missteps, intense competition, and ongoing legal probes. The stock is suitable only for high-risk investors betting on long-term AAM adoption.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →